Market research
002603.SHE Shijiazhuang Yiling Pharmaceutical Co., Ltd
SHE CNY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 25B
- P/E ratio
- 18.43
- Analyst target
- 20.855
- Dividend yield
- 3.3%
- Beta
- 0.41
Profile
Instrument facts
- Exchange
- SHE
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CNE1000015S0
- Market cap
- 25B
- P/E ratio
- 18.43
- Analyst target
- 20.855
- Dividend yield
- 3.3%
- Beta
- 0.41
About
About Shijiazhuang Yiling Pharmaceutical Co., Ltd
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and personal protective equipment products; and TCM formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Research context
Shijiazhuang Yiling Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 002603.SHE discussion.
5 years, 6 months ago
Shijiazhuang Yiling Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 25.2% below its 200 day moving average.
From a valuation standpoint, the stock is 61.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Shijiazhuang Yiling Pharmaceutical Co., Ltd's total revenue rose by 32.6% to $2B since the same quarter in the previous year.
Its net income has increased by 856.1% to $302M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.5% to $-248M since the same quarter in the previous year.
Based on the above factors, Shijiazhuang Yiling Pharmaceutical Co., Ltd gets an overall score of 4/5.